Lexicon Pharmaceuticals | LXRX - Cash And Equivalent

Stock Price
1.31
Daily Change
0 0%
Monthly
5.65%
Yearly
66.90%
Q1 Forecast
2.01

Lexicon Pharmaceuticals reported $21.36M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Abbott USD 7.51B 560M Sep/2025
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Akebia Therapeutics USD 166.44M 29.14M Sep/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Coherus Biosciences USD 103.35M 113.54M Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Halozyme Therapeutics USD 419.66M 357.8M Sep/2025
Illumina USD 1.42B 368M Dec/2025
Insmed USD 334.76M 949.56M Sep/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Lexicon Pharmaceuticals USD 21.36M 41.52M Jun/2025
MacroGenics USD 80.13M 50.56M Sep/2025
MannKind USD 127.39M 70.39M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
United Therapeutics USD 1.34B 253M Sep/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025